Is there life after technetium what is the potential for developing new broad-based radionuclides?

Seminars in Nuclear Medicine

Volumn 26, Issue 2, 1996, Pages 119-131

  Srivastava, Suresh C ^a,b  

^a Department ^*  (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; RADIOISOTOPE; TECHNETIUM;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; GAMMA RADIATION; HUMAN; MAGNETIC AND ELECTROMAGNETIC EQUIPMENT; NEOPLASM; NUCLEAR MEDICINE; RADIOIMMUNOTHERAPY; RADIOTHERAPY; REVIEW; SCINTISCANNING; UNITED STATES;

GAMMA RAYS; HUMANS; NEOPLASMS; NUCLEAR MEDICINE; PARTICLE ACCELERATORS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIONUCLIDE IMAGING; RADIOTHERAPY; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED; UNITED STATES;

EID: 0030122092     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-2998(96)80033-X     Document Type: Article

References (78)

1. Richards P, Tucker WD, Srivastava SC: Technetium-99m: An historical perspective. Int J Appl Radiât Isot 33:793-799,1982
2. Srivastava SC, Richards P: Technetium labeled compounds, in Rayudu GVS (ed): Radiotracers for Medical Applications, vol I. Boca Raton, FL, CRC Press, 1983, pp 107-185
3. Srivastava SC, Mease RC: Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. Nucl Med Biol 18:589-603,1991
4. Srivastava SC, Richards P, Som P, et al: Ruthenium-97 labeled compounds-a new class of radiopharmaceuticals, in Horst W, Wagner HN, Buchanan J (eds): Frontiers in Nuclear Medicine, Heidelberg, Germany, Springer-Verlag KG, 1980, pp 123-133
5. Oster ZH, Som P, Gil MC, et al: Ruthenium-97DTPA: A new radiopharmaceutical for cisternography. J Nucl Med 22:269-273, 1981
6. Schachner ER, Gil MC, Atkins HL, et al: Ruthenium97-hepatobiliary agents for delayed studies of the biliary tract I: Ru-97-PIPIDA: Concise communication. J Nucl Med 22:352-357, 1981
7. Helson L, Rosenspire K, Kapellans A, et al: Uptake of ruthenium-labeled transferrin in healing wounds. Int J Nucl MedBiol 10:237-239, 1983
8. Zanzi I, Srivastava SC, Meinken GE, et al: A new cholescintigraphic agent: Ru-97-DISIDA. Nucl Med Biol 16:397-403, 1989
9. Zanzi I, Markowitz J, Srivastava SC, et al: The use of a new radiopharmaceutical, ruthenium-97-DISIDA, and of Tc-99m-sulfur colloid for the simultaneous evaluation of duedenogastric reflux and gastric emptying. Nucl Med Commun 13:76-81, 1992
10. Srivastava SC, Mease RC, Meinken GE, et ai: Development of a new radiolabel (lead-203) and new chelating agents for labeling monoclonal antibodies for imaging. Acta Radiol 374:135-140,1990
11. Mausner LF, DasGupta AK, Srivastava SC: Production of 203Pb by proton irradiation of Bi. J Label Comp Radiopharm 30:117-119,1991
12. Clem R, Lambrecht RM, Mirzadeh S, et al: Radiochemistry of lead-203 for radiolabeling antibody conjugates. J Label Comp Radiopharm 30:327,1991 (abstr)
13. Welch MJ: Positron emission tomography, in Moody DC, Peterson EJ (eds): in The Role of a High Current Accelerator in the Future of Nuclear Medicine. Proc Department of Energy Workshop. Los Alamos, NM, Conference LA 11576-C, 1989, pp 19-23
14. Srivastava SC, Mausner LF (ed): Radiolabeled monoclonal antibodies: Chemical, diagnostic and therapeutic investigations. Nucl Med Biol 13:303-495,1986
15. Srivastava SC: Radiolabeled Monoclonal Antibodies for Imaging and Therapy. New York, NY, Plenum Press, 1988
16. Britton KE, Mather SJ, Granowska M: Radiolabelled monoclonal antibodies in oncology III. Radioimmunotherapy. Nucl Med Commun 12:333-347,1991
17. Larson SM, Digvi CR, Scott A, et al: Current status of radioimmunotherapy. Nucl Med Biol 21:785-792,1994
18. Mausner LF, Srivastava SC: Selection of radionuclides for radioimmunotherapy. Med Phys 20:503-509, 1993
19. Feinendegen LE: Biological damage from the Auger effect: Possible benefits. Radiât Environ Biophys 12:85-99, 1975
20. Adelstein SJ, Kassis AI: Radiobiologie implications of the microscopic distribution of energy from radionuclides. Nucl Med Biol 14:165-169,1987
21. Kassis AI, Adelstein SJ, Haycock CK, et al: Lethality of Auger electrons from the decay of Br-77 in the DNA of mammalian cells. Radiât Res 90:362-373,1982
22. Jungerman JA, Yu Kin-Hung P, Zanelli CI: Radiation absorbed dose estimates at the cellular level for some electron emitting radionuclides for radioimmunotherapy. Int J Appl Radiât Isot 35:883-888,1984
23. Wessels BW, Rogus RD: Radionuclide selection and model absorbed dose calculations for radiolabeled tumorassociated antibodies. Med Phys 11:638-645,1984
24. Humm JL: Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 27:1490-1497,1986
25. Griffith MH, Yorke ED, Wessels BW, et al: Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med 10:1795-1809,1988
26. O'Donoghue JA, Bardies M, Wheldon TE: Relationships between tumor size and curability for uniformly targeted therapy with beta emitting radionuclides. J Nucl Med 36:1902-1909,1995
27. Yorke ED, Beaumier PL, Wessels BW, et al: Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: A predictive model based on mouse pharmacokinetics. Nucl Med Biol 18:827-835,1991
28. Srivastava SC: Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother Radiopharm, 1996 (in press)
29. Srivastava SC, Meinken GE: Correlating labeling chemistry and in vitro test results with the biological behavior of radiolabeled proteins. Int J Biol Markers 1:111-120,1986
30. Deshpande SV, DeNardo SJ, Meares CF, et al: Copper-67-labeled monoclonal antibody LYM-1, a potential radiopharmaceutical for cancer therapy: Labeling and biodistribution in RAJI tumored mice. J Nucl Med 29:217-225,1988
31. DasGupta AK, Mausner LF, Srivastava SC: A new separation procedure for Cu from proton irradiated Zn. Int J Appl Radial Isot 42:371-376,1991
32. Mausner LF, Srivastava SC, Kolsky KL, et al: Development and evaluation of copper-67 labeled DOTA and TETA immunoconjugates for radioimmunotherapy. J Label Comp Radiopharm 35:374-376,1994
33. Srivastava SC, Mausner LF, Mease RC, et al: Development and evaluation of 67Cu and I53Sm labeled conjugates for tumor radioimmunotherapy. Int J Radiopharmacognosy 33:92-101,1995
34. Mirzadeh S, Mausner LF, Srivastava SC: Production of no-carrier-added Cu-67. Int J Appl Radiât Isotopes 37:29-36,1986
35. Mausner LF, Kolsky KL, Mease RC, et al: Production and evaluation of Sc-47 for radioimmunotherapy. J Label Comp Radiopharm 32:388-390,1993
36. Mausner LF, Joshi V, Kolsky KL, et al: Evaluation of chelating agents for radioimmunotherapy with scandium47. J Nucl Med 36:104P, 1995 (abstr)
37. Srivastava SC, Meinken GE, Mausner LF, et al: Nuclear, chemical, and mechanistic considerations in the use of 7mSn (14 +) DTPA in relation to 186Re-HEDP and other agents for bone pain therapy, in Nicolini M, Bandoli G, Mazzi U (eds): Technetium and Rhenium in Chemistry and Nuclear Medicine. Padova, Italy, SG Editorial!, 1994, pp 287-292
38. Ehrhardt G, Ketring AR, Turpin TA, et al: An improved tungsten-188/rhenium-188 generator for radiotherapeutic applications. J Nucl Med 28:656-657,1987
39. Callahan AP, Rice DE, Knapp FF: 188Re for therapeutic applications from an alumina-based 188W/188Re radionuclide generator. Nucl Compact 1:3-5,1989
40. Virzi F, Rusckowski M, Hnatowich DJ: Improving the direct labeling of antibodies with Re-188. J Nucl Med 35:206P, 1995 (abstr)
41. Zamora PO, Guhlke S, Bender H, et al: Radiotherapy with Re-188-RC160, a directly labeled somatostatin analog in athymic mice with PC-3 tumors (human prostate carcinoma). J Nucl Med 36:42P, 1995 (abstr)
42. Order SE, Klein JL, Leichner PK, et al: Yttrium-90 antiferritin. A new therapeutic radiolabeled antibody. Int J Radiât Oncol Biol Phys 12:227-281,1986
43. Kosmas C, Maraveyas A, Gooden CS, et al: Antichelate antibodies after intraperitoneal Y-90 labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J Nucl Med 36:746-753,1995
44. Hnatowitch DJ, Chinol M, Siebecker DA, et al: Patient biodistribution of intraperitoneally administered yttrium-90 labeled antibody. J Nucl Med 29:1428-1435,1988
45. Carasquillo JA, Kramer B, Fleisher T, et al: In-Ill versus Y-90 T101 biodistribution in patients with hematopoietic malignancies. J Nucl Med 32:970,1991 (abstr)
46. Breitz H, Ratliff B, Schroff R, et al: Phase I studies of 186Re whole MoAb and F(ab')2 fragment for radioimmunotherapy in solid tumors. J Nucl Med 31:724-725,1990
47. Wilbur DS: Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody Immunocon Radiopharm 4:85-97,1990
48. Atcher RN, Friedman AM, Hines JJ: An improved generator for the production of 212Pb and 212Bi from 224Ra. Int J Appl Radiât Isot 39:283-286,1988
49. Ruegg CL, Anderson-Berg WT, Brechbiel M, et al: Improved in-vivo stability and targeting of bismuth labeled antibody. Cancer Res 50:4221-4226,1990
50. Harrison A, Royle L: Preparation of a 211At-IgG conjugate which is stable in-vivo. Int J Appl Radiât Isot 35:1005-1008,1984
51. Zalutsky MR, Garg PK, Friedman HS: Labeling monoclonal antibodies and F(ab')2 with the a-particleemitting nuclide astatine-211: Preservation of immunoreactivity and in-vivo localizing capacity. Proc Natl Acad Sci USA 86:7149-7153,1989
52. McEwan AJB: Radiopharmaceuticals for palliative treatment of painful bone métastases. New Perspectives in Cancer Diagnosis and Management. 2:24-31,1994
53. Silberstein EB, Elgazzar AH, Kapilivsky A: Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous métastases. Semin Nucl Med 22:17-27,1992
54. Maxon HR, Schröder LE, Hertzberg VS, et al: Rhenium-186(Sn)HEDP for treatment of painful osseous métastases: Results of a double-blind crossover comparison with placebo. J Nucl Med 32:1877-1881, 1991
55. Goeckler WF, Edwards B, Volkert WA, et al: Skeletal localization of samarium-153 chelates: Potential therapeutic bone agents. J Nucl Med 28:495-504,1987
56. Simon J, Goeckler WF, Edwards B, et al: SmEDTMP-153, a potential therapeutic bone agent. J Label Comp Radiopharm 23:1344-1346,1986
57. Turner HJ, Caringbold PG, Hetherington EL, et al: A phase I study of 153Sm-EDTMP therapy for disseminated skeletal métastases. J Clin Oncol 30:1814-1818,1989
58. Srivastava SC, Meinken GE, Richards P, et al: The development and in-vivo behavior of tin containing radiopharmaceuticals. I: Chemistry, preparation, and biodistribution in small animals. Int J Nucl Med Biol 12:167-174,1985
59. Atkins HL, Mausner LF, Srivastava SC, et al: Human biodistribution of Sn-117m(4+)DTPA: A new agent for palliative therapy of painful osseous métastases. Radiology 186:279-283,1993
60. Atkins HL, Mausner LF, Srivastava SC, et al: Tin117m(4+)-DTPA for palliation of bone from osseous métastases: A pilot study. J Nucl Med 36:725-729,1995
61. American Cancer Society: Cancer facts and figures1994. Atlanta, GA. American Cancer Society, Inc, 1994, pp 1-28
62. Lamb JF, Kramer HH: Commercial production of radioisotopes for nuclear medicine, in Rayudu GVS (ed): Radiotracers for Medical Applications, vol I. Boca Raton, FL, CRC Press, 1983
63. Volkert WA, Goeckeler WF, Ehrhardt GJ, et al: Therapeutic radionuclides: Production and decay property considerations. J Nucl Med 32:174-185,1991
64. Srivastava SC, Mausner LF: Production and supply of radioisotopes with high-energy particle accelerators: Current status and future directions. Proceedings of the 21st Japan Conference on Radiation and Radioisotopes. Japan Atomic Industrial Forum, B-550,1994, pp 1-11
65. Proceedings of the Purdue National Biomédical Tracer Facility Workshop. Purdue University, West Lafayette, IN,1992
66. 117mSn with the Szilard-Chalmers process. J Label Comp Radiopharm 16:177-178,1989
67. Larson SM, Pentlow KS, Volkow ND, et al: PET scanning of I-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 33:2020-2023,1992
68. Kozak RW, Atcher RW, Gansow OA, et al: Bismuth212 labeled anti-TAC monoclonal antibody: a particle emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci USA 83:474-478,1986
69. Tilyou SM: Energy agency examines radioisotope needs in preparation for the future. J Nucl Med 31:13A19A, 1990(abstr)
70. Proceedings of the Department of Energy Workshop on The Role of a High-Current Accelerator in the Future of Nuclear Medicine. Los Alamos, NM, Conference LA 11576-C,1989
71. US Department of Energy, Health and Environmental Research Advisory Committee, Subcommittee on Nuclear Medicine: Review of the Office of Health and Environmental Research Program: Nuclear medicine. Washington, DC, US Department of Energy, August, 1989
72. Rojas-Burke J: Early closing of accelerator could impede nuclear medicine research. J Nucl Med 34:51N, 1993 (abstr)
73. Vera-Ruiz H: Cyclotron facilities with radionuclide production programs in member states. Vienna, Austria, International Atomic Energy Agency, 1983
74. Mausner LF, Mirzadeh S, Schnakenberg H, et al: The design and operation of the upgraded BLIP facility for radionuclide research and production. Appl Radiât Isot 41:367-374,1990
75. Moody DC, Peterson EJ: Proc Department of Energy workshop on the role of a high-current accelerator in the future of nuclear medicine. Los Alamos, NM, Conference LA11576-C, 1989, pp 1-8
76. National Biomédical Tracer Facility: Planning and feasibility study. Holmes RA, PI, Washington, DC, US Department of Energy, 1991
77. Rojas-Burke J: Energy department proposes two isotopes initiatives. J Nucl Med 34:47N-48N, 1993
78. Adelstein SJ, Manning FJ (ed): Isotopes for Medicine and the Life Sciences. Washington, DC, National Academy Press, 1995, pp 1-132